Lidoflazine: Double-blind trial of a new coronary vasodilator in angina pectoris
| Autor: | G. Palmborg, J. Philipson, N. Egelius, M. Jemt, B. Brantmark, N. Rönnegård, E. Fabricius |
|---|---|
| Rok vydání: | 1973 |
| Předmět: |
Male
medicine.medical_specialty Time Factors Vasodilator Agents Statistics as Topic Pharmacology toxicology Placebo Piperazines Angina Pectoris Placebos Double blind Angina Electrocardiography Nitroglycerin Internal medicine medicine Animals Humans Pharmacology (medical) Aged Lidoflazine Pharmacology Clinical Trials as Topic business.industry Digitalis Glycosides General Medicine Middle Aged medicine.disease Clinical trial Cardiology Coronary vasodilator business medicine.drug |
| Zdroj: | European Journal of Clinical Pharmacology. 6:156-162 |
| ISSN: | 1432-1041 0031-6970 |
| DOI: | 10.1007/bf00558279 |
| Popis: | Lidoflazine, a new coronary vasodilator, has been tested in 31 cases of angina pectoris in a double-blind cross-over study. It diminished significantly the frequency of attacks and nitroglycerine consumption of the more severe cases, but its effects were less marked in milder cases. The results are discussed in relation to other anti-anginal drugs. The necessity for a preliminary run-in period in studies of angina pectoris is emphasized and the occurrence of carry-over effects between lidoflazine and the placebo is discussed. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink